Idenix Clinical Hold On Two Hep C Programs May Be Resolved By Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase I study combining two of the biotech's drugs reveals liver problems.
You may also be interested in...
Idenix Can Move Ahead On Studies Of HCV Candidate IDX184 With Partial Lifting Of FDA Hold
Company must negotiate future planned studies with FDA but has go-ahead for a biovailability study and then a Phase IIb trial.
Idenix Can Move Ahead On Studies Of HCV Candidate IDX184 With Partial Lifting Of FDA Hold
Company must negotiate future planned studies with FDA but has go-ahead for a biovailability study and then a Phase IIb trial.
Novartis Plans to Move Infectious Disease Research Group to the Bay Area
The company has hired a high-profile professor with a nose for virus sleuthing as its new ID chief, and it will start shifting its 120-member R&D staff from the Boston area next year.